Contact

Our portfolio

Regenesance

Regenesance focuses on antibody engineering to treat neurodegenerative diseases and immune-mediated disorders. The company licenses its technology to Complement Pharma, aiming to develop therapies for conditions like ALS and multiple sclerosis. The company leverages groundbreaking research to improve patient outcomes.

  • Institute: Amsterdam UMC
Industry: Immunology, Therapeutics
  • Founding year: 2009
Visit website

Want to get in contact about Regenesance?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Sightcorp
Specializing in AI-powered audience intelligence, Sightcorp provides automated facial analysis and emotion recognition technology.

GuanaRep

GuanaRep
Repurposing the obsolete hypertension drug Guanabenz for the treatment of Vanishing White Matter.
Kepler Vision Technologies
Improving elderly care with Night Nurse, an AI-powered patient monitoring system.
DCPrime
Pioneering cancer vaccines, DCPrime leverages its DCOne® dendritic cell technology to develop innovative immunotherapies.
Sightcorp
Specializing in AI-powered audience intelligence, Sightcorp provides automated facial analysis and emotion recognition technology.

GuanaRep

GuanaRep
Repurposing the obsolete hypertension drug Guanabenz for the treatment of Vanishing White Matter.
Kepler Vision Technologies
Improving elderly care with Night Nurse, an AI-powered patient monitoring system.
DCPrime
Pioneering cancer vaccines, DCPrime leverages its DCOne® dendritic cell technology to develop innovative immunotherapies.
Explore full AAV portfolio
Contact